Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention

The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Stephanie R. Land, PhD
D. Lawrence Wickerham, MD
Joseph P. Costantino, DrPH
Marcie W. Ritter, PhD
Victor G. Vogel, MD, MHS
Myoungkeun Lee, MS
Eduardo R. Pajon, MD
James L. Wade III, MD
Shaker Dakhil, MD
James B. Lockhart, Jr, MD
Norman Wolmark, MD
Patricia A. Ganz, MD

The National Surgical Adjuvant Breast and Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) was a multicenter, double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene (60 mg/d for 5 years) compared with tamoxifen (20 mg/d for 5 years) in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. In addition, it was hypothesized that raloxifene would have a better safety profile with respect to uterine cancer and a number of patient-reported symptoms and would provide a potential alternative to tamoxifen in the prevention of breast cancer in postmenopausal women. Therefore, measurement of patient-reported outcomes was an important secondary objective of the STAR trial.

Context  Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown.

Objective  To compare the differences in patient-reported outcomes, quality of life [QOL], and symptoms in Study of Tamoxifen and Raloxifene (STAR) participants by treatment assignment.

Design, Setting, Participants, and Interventions  STAR was a double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene vs tamoxifen in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. Between July 1, 1999, and November 4, 2004, 19,747 participants were enrolled at centers throughout North America, with a median potential follow-up time of 4.6 years (range, 1.2-6.5 years). Patient-reported symptoms were collected from all participants using a 36-item symptom checklist. Quality of life was measured with the Medical Outcomes Study Short-Form Health Survey (SF-36), the Center for Epidemiologic Studies-Depression (CES-D), and the Medical Outcomes Study Sexual Activity Questionnaire in a substudy of 1,983 participants, median potential follow-up 5.4 years (range, 4.6-6.0 years). Questionnaires were administered before treatment, every 6 months for 60 months and at 72 months.

Main Outcome Measures  Primary QOL end points were the SF-36 physical (PCS) and mental (MCS) component summaries.

Results  Among women in the QOL analysis, mean PCS, MCS, and CES-D scores worsened modestly over the study’s 60 months, with no significant difference between the tamoxifen (n = 973) and raloxifene (n = 1,010) groups (P > .2). Sexual function was slightly better for participants assigned to tamoxifen (age-adjusted repeated measure odds ratio, 1.22%; 95% CI, 1.01-1.46). Of the women in the symptom assessment analyses, the 9,769 in the raloxifene group reported greater mean symptom severity over 60 months of assessments than the 9,743 in the tamoxifen group for musculoskeletal problems (1.15 vs 1.10, P = .002), dyspareunia (0.78 vs 0.68, P < .001), and weight gain (0.82 vs 0.76, P < .001). Women in the tamoxifen group reported greater mean symptom severity for gynecological problems (0.39 vs 0.19, P < .001), vasomotor symptoms (0.96 vs 0.85, P < .001), leg cramps (1.10 vs 0.91, P < .001), and bladder control symptoms (0.88 vs 0.73, P < .001).

Conclusions  No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamoxifen group reported better sexual function. Although mean symptom severity was low among these postmenopausal women, those in the tamoxifen group reported more gynecological problems, vasomotor symptoms, leg cramps, and bladder control problems, whereas women in the raloxifene group reported more musculoskeletal problems, dyspareunia, and weight gain.

Trial Registration  clinicaltrials.gov Identifier: NCT00003906

See also pp 2727 and 2784.
Tamoxifen citrate and raloxifene hydrochloride are selective estrogen receptor modulators that respectively have been approved by the US Food and Drug Administration for prevention of breast cancer and osteoporosis.1,2 The acceptability of drugs that are used for prevention often rests on their efficacy as well as their adverse-effect profiles. Selective estrogen receptor modulators bind competitively with the estrogen receptor in various tissues and can have properties of both an estrogen antagonist and agonist. This has resulted in patient reports of vasomotor symptoms with both tamoxifen and raloxifene.3,4 With tamoxifen, there have also been patient-reported symptoms of estrogen excess, eg, vaginal discharge and vaginal bleeding.3

The patient-reported outcome study for the STAR trial builds directly on the quality of life (QOL) outcome assessment in the Breast Cancer Prevention Trial (BCPT), which compared tamoxifen with placebo in the prevention of breast cancer.1,3,5 In that trial, we assessed patient-reported outcomes using several established self-report measures for which normative data were available in the general population of healthy women and we established a comprehensive symptom checklist.5 We found no significant differences in QOL, depression, or sexual functioning between patients treated with tamoxifen or placebo but noted increased rates of hot flashes, night sweats, and vaginal discharge among women treated with tamoxifen.3,6,9

In 1999, when the STAR trial was being designed, relatively little was known about how raloxifene affected patient outcomes. In the Multiple Outcomes of Raloxifene Evaluation (MORE), a double-blind, randomized and placebo-controlled study examining osteoporosis prevention in older postmenopausal women, all participants were questioned about adverse events at each visit. Raloxifene-treated participants were found to have modest but significant increases in observer-reported hot flashes and leg cramps compared with placebo but no significant differences in vaginal bleeding.6

The STAR trial provided an opportunity to compare patient-reported outcomes with both of these selective estrogen receptor modulators in the setting of a double-blind, randomized, placebo-controlled trial. We expected STAR to show no difference in overall mental health, physical health, or QOL between tamoxifen and raloxifene. However, based on the extant data, we expected to see more frequent vasomotor and gynecological symptoms (eg, vaginal bleeding, discharge) with tamoxifen and more frequent leg cramps with raloxifene. This is the first report of the patient-reported outcomes in the STAR trial.

METHODS
Participants
The study eligibility, recruitment procedures, and clinical outcomes are published elsewhere.10 Briefly, to be eligible for participation, a woman had to be postmenopausal, to be aged 35 years or older, and to have at least a 5-year predicted breast cancer risk of 1.66% as determined by the modified Gail model.11-14

Participants provided written informed consent for the study. The race of participants was determined by the modified Gail model11-14 and to have at least a 5-year predicted breast cancer risk of 1.66% as determined by the modified Gail model11-14. Women were randomly assigned to receive 5 years of therapy with either 20 mg/d of tamoxifen and a placebo or 60 mg/d of raloxifene and a placebo. The protocol-defined monitoring plan called for a final analysis and release of findings when 327 invasive breast cancer cases had been diagnosed in the total population. The protocol and consent form were approved by the National Cancer Institute and the institutional review boards of all participating institutions. All participants provided written informed consent for the study. The race of participants was determined by the modified Gail model11-14.

Patient-Reported Outcome Assessment
The QOL assessment used standardized measures that were identical to those used in the BCPT.5 They will be described briefly. Health-related QOL was assessed with the Medical Outcomes Study Short Form-36 (SF-36).15-18 which contains 8 individual subscales. Each subscale is scored from 0 to 100, with 100 being the most favorable score. The scales are physical functioning, role functioning, physical, bodily pain, social functioning, emotional well-being, role functioning, emotional, vitality, and general health perceptions.19 General population norms are available for this instrument.19 The instrument can also be scored as 2 component summary scales—one for physical functioning (PCS) and a second for mental health (MCS).20 The data for these component summary scales are presented as T scores with a normal healthy population mean score set at 50 and a score of 60 or 40 representing an SD above or below the mean, respectively. This instrument has been widely used in recent health surveys and in multicenter clinical trials.21,22

Depressive symptoms were measured with the Center for Epidemiologic Studies—Depression (CES-D) scale,23 which is a 20-item self-report scale developed for the general population to measure depressive symptoms over the past week. Normative data are available from community-based samples.24,25 The instrument has excellent reliability and validity, including use with multiethnic samples.23 Responses to the CES-D are rated on a 4-point scale, and the instrument total score ranges from a minimum score of 0 to a maximum of 60. A higher score on the CES-D indicates a greater risk of depression, with scores greater than or equal to 16 indicating potentially significant levels of depression.23 The CES-D has been used in recent studies of healthy women participating in large clinical trials.26

Sexual functioning was assessed using a modification of the Medical Outcomes Study Sexual Functioning Scale27 that had been successfully used in the prior BCPT.3,5 First participants were asked a screening question about whether they had been sexually active in the past 6 months. Those responding affirmatively were then asked spe...
specifically about the past 4 weeks regarding how much of a problem each activity or function had been, with a scale of 0 as being not a problem; 1, a little problem; 2, a definite problem; and 3, a serious problem. The specific questions were “lack of sexual interest,” “difficulty in becoming sexually aroused,” “unable to relax and enjoy sex,” and “difficulty in having orgasm.”

The 43-item symptom checklist that had been used in the BCPT was shortened based on the data from the placebo comparison and from a preliminary psychometric evaluation of the scale items. This resulted in a 36-item symptom checklist that included a new item asking about leg cramps, as well as additional items to cover other potential adverse symptoms. The responses use a Likert-type scale and range from 0 to 4, representing the categories “not at all,” “slightly,” “moderately,” “quite a bit,” and “extremely,” respectively.

Symptom information was collected from all STAR participants using this modified symptom checklist. Based on statistical power considerations, the decision was made to collect QOL information from a smaller subset of participants. For practical reasons, this subset was restricted to English-speaking participants enrolled at institutions in the Community Clinical Oncology Program (CCOP), a National Cancer Institute–sponsored network for conducting cancer prevention and treatment clinical trials by community medical practitioners. Eligible CCOP institutions elected to participate in the QOL substudy and indicated the completion of their institutional review board approval by submitting a study initiation form to the NSABP. From each institution's initiation date to the date that accrual to the substudy was closed, all participants enrolled at participating institutions were considered enrolled in the substudy.

Questionnaires were administered in the office at clinic visits, although telephone or mail administration was also allowed when necessary. Clinical staff were instructed to allow the participants enrolled at participating institutions in the Community Clinical Oncology Program to complete the questionnaire on their own without help interpreting the items. Institutions were also instructed to submit a QOL Missing Data form in lieu of a QOL form for any assessment that was not obtained. The QOL Missing Data form is completed by clinical staff and requests information about the reason(s) for the missed assessment. Both the symptom checklist and QOL questionnaires were administered at baseline (before treatment), every 6 months until 60 months, and at 72 months. However, at the time of data file closure for the present analysis (December 31, 2005), only a small number of study participants had reached the 72-month assessment. Therefore, the present analysis is restricted to assessments performed through 60 months on study.

Statistical Methods
For the QOL study, the protocol-specified sample size of 1670 evaluable participants provides a power of greater than 99% for the repeated-measures analysis of variance of 2 primary end points at a 2-sided significance level of .025, assuming a mean treatment difference equal to one half of an SD. (The study was overpowered for the primary analyses to allow adequate power for secondary analyses.) It was estimated that an accrual goal of 2000 participants would yield adequate data, allowing for study attrition or missing data.

All analyses were performed using 2-sided tests with an intent-to-treat approach including all women with follow-up assessments available. Major analyses were also repeated once restricted to those assessments performed before treatment discontinuation and a second time with the same restriction and including only participants who discontinued treatment for nonprotocol reasons.

Using χ² tests, participant characteristics were compared between the QOL substudy participants and contemporaneously accrued participants not in the QOL substudy. The time from randomization to treatment noncompliance (discontinuation of treatment in the absence of cancer diagnosis, stroke, or other event that was listed in the protocol as mandating discontinuation) was compared between treatment groups with Kaplan-Meier and log-rank methods. Primary QOL end points were the SF-36 MCS and PCS. For these 2 primary end points, a P value of less than .025 was the significance threshold. All secondary analyses were performed at significance level of .05. The NSABP policy does not require adjusting for multiple comparisons in secondary analyses, particularly for end points related to safety. Analyses were performed using SAS version 8.2 (SAS Institute Inc, Cary, NC).

The PCS and MCS of the SF-36 and the CES-D scores were compared between treatment groups in repeated measures (mixed effects) analysis. Baseline scores were included as covariates. The proportion sexually active was compared by treatment group and age using logistic mixed-effects modeling. The severity scores for sexual function items were averaged for all time points after baseline, then compared by treatment group using analysis of covariance, controlling for baseline scores and age. Based on results from the NSABP Project BCPT Study and on literature about menopause, we had a priori hypotheses that vasomotor symptoms would be worse in women younger than 60 years and that sexual activity would be less common among women older than 60 years. Therefore, we systematically included age relative to 60 years in our analyses of sexual function and symptoms.

For the analysis of the symptom assessment, the following subscales were selected based on previous psychometric validation of the BCPT symptom checklist in several settings and in research by David Cell, PhD, and colleagues (unpublished data, 2006): (1) musculoskeletal: joint pain, muscle stiffness, general aches and pains; (2) vasomotor: night sweats, hot flashes, and cold sweats; (3) gastrointestinal: vomiting, nausea; (4) dyspareunia: vagi-
nal dryness, pain with intercourse; (5) bladder: difficulty with bladder control (when laughing or crying) and difficulty with bladder control (at other times); (6) gynecological: vaginal discharge, genital itching or irritation, and vaginal bleeding or spotting. The subscales form more robust measures of each symptom cluster than would be available from the individual items.

For each symptom assessment subscale and 3 single items (forgetfulness, weight gain, and leg cramps), severity scores for each patient were averaged over all time points after baseline and through 60 months. Regression analyses were performed to compare the average severity between treatment groups and age groups (≥60 vs <60 years), controlling for the baseline severity value. Effect sizes for scales were computed as the mean treatment difference divided by the SD at baseline. For the 4 symptom domains that showed the largest treatment differences in the primary analyses, further exploration was performed with multivariable logistic regression to determine the effect of participant characteristics (age at baseline, hysterectomy status, and race), baseline symptom severity and treatment on the proportion of participants who experienced an increase in symptom checklist scale severity of at least 1 point from baseline to 6 months.

RESULTS
The trial opened on July 1, 1999. Accrual was completed November 4, 2004, at which time 19,747 women had been enrolled. Almost 200 clinical centers throughout North America participated in this study. The full study population of 19,747 participants was eligible for the symptom checklist assessment. The QOL study enrolled 1983 participants between January 4, 2000, and May 31, 2001, with 973 assigned to receive tamoxifen and 1010 assigned to receive raloxifene. As of December 31, 2005, the median potential follow-up time was 4.6 years in the full cohort and 5.4 years among the QOL participants. Among QOL participants, there were no significant differences in participant characteristics by treatment group (Table 1). Characteristics of those participating in QOL substudy were comparable with women accrued concurrently at nonparticipating institutions with the exception of 2 small differences: a 3% excess of women with atypical hyperplasia among the nonparticipants and a 3% excess of women with hysterectomy among the participants. The characteristics of all participants who provided a baseline symptom assessment are also provided elsewhere.

The mean duration of treatment up to the time of data file closure in the randomized STAR population was 3.03 years (range, 0-5 years) and 3.14 years (range, 0-5 years) among the QOL participants. Among QOL participants, there were no significant differences in participant characteristics by treatment group (Table 1). Characteristics of those participating in QOL substudy were comparable with women accrued concurrently at nonparticipating institutions with the exception of 2 small differences: a 3% excess of women with atypical hyperplasia among the nonparticipants and a 3% excess of women with hysterectomy among the participants. The characteristics of all participants who provided a baseline symptom assessment are also provided elsewhere.

The mean duration of treatment up to the time of data file closure in the randomized STAR population was 3.03 years (range, 0-5 years) and 3.14 years (range, 0-5 years) among the QOL participants. Among QOL participants, there were no significant differences in participant characteristics by treatment group (Table 1). Characteristics of those participating in QOL substudy were comparable with women accrued concurrently at nonparticipating institutions with the exception of 2 small differences: a 3% excess of women with atypical hyperplasia among the nonparticipants and a 3% excess of women with hysterectomy among the participants. The characteristics of all participants who provided a baseline symptom assessment are also provided elsewhere.

The mean duration of treatment up to the time of data file closure in the randomized STAR population was 3.03 years (range, 0-5 years) and 3.14 years (range, 0-5 years) among the QOL participants. Among QOL participants, there were no significant differences in participant characteristics by treatment group (Table 1). Characteristics of those participating in QOL substudy were comparable with women accrued concurrently at nonparticipating institutions with the exception of 2 small differences: a 3% excess of women with atypical hyperplasia among the nonparticipants and a 3% excess of women with hysterectomy among the participants. The characteristics of all participants who provided a baseline symptom assessment are also provided elsewhere.
PATIENT-REPORTED OUTCOMES WITH TAMOXIFEN VS RALOXIFENE

Figure 1. Medical Outcomes Study Short Form-36 Mental and Physical Health Component Summaries and Center for Epidemiologic Studies–Depression Scores Over Time, Averaged by Treatment Group

High scores for the Medical Outcomes Study Short Form-36 (SF-36) mental and physical health components indicate better status; high scores on the Center for Epidemiologic Studies–Depression (CES-D) indicate more depressive effect. The P value is based on repeated measures analysis. Mental and physical health component scores were scaled to have a population normative SD of 10 units. The SD range for the mental health component score is 7.65 to 9.42; for the physical component score, it is 8.52 to 10.57. The range for the CES-D score is 6.80 to 8.73 units.

Figure 2. Sexual Activity (Percentage Active) Over Time by Age and Treatment Group

The P value is based on repeated measures analysis.

Quality-of-life forms completion was high, with 95% at baseline, a range of 76% to 86% at all time points from 6 to 60 months, and no systematic difference between treatment groups. Symptom-checklist form completion was also high, with 99% submission of the baseline form, submission rates ranging from 83% to 95% for the other time points, and no difference between treatment groups greater than 1% at any point. Forms were not expected after death or consent withdrawal, which occurred at some point during follow-up for 197 women (1.0%) in the tamoxifen and 1352 (6.8%) in the raloxifene groups. Quality of life Missing Data forms were submitted for 41% of the assessments that were missed. The reasons for the missed assessments given were inadvertent staff error (61% of submitted QOL Missing Data forms), participant refused or objected to burden of completing form (13%), participant failed to appear for scheduled follow-up visit (8%), participant had withdrawn informed consent (2%), and participant failed to respond to telephone or mail request (25%). (The percentages are not additive because multiple reasons were permitted.) There was no difference in the distributions of reasons by treatment group.

QOL Outcomes

Mean MCS and PCS scores (Figure 1) declined modestly over the 60 months of assessments with no significant difference between tamoxifen and raloxifene (P = .23, MCS and P = .21, PCS). There were significant differences in favor of raloxifene in 2 of the SF-36 subscales, but of small magnitude: role physical (P = .03, mean difference 2.4, effect size, 0.1) and social function (P = .02; mean difference, 1.0; effect size, 0.1). Mean CES-D scores worsened slightly after study initiation in both treatment groups (Figure 1) but with no significant difference between tamoxifen and raloxifene (P = .61).

FIGURE 2 displays the percentage reporting being sexually active over time by treatment and age groups. Age was significant (P < .001) with an odds ratio of 0.55 (95% confidence interval, 0.46-0.66), indicating a decrease among women older than 60 years. Treatment was also significant (P = .04), with an odds ratio of 1.22 (95% confidence interval, 1.01-1.46), indicating a slightly higher percentage sexually active among women in the tamoxifen group. The maximum difference was 7% at the 30-month assessment among women younger than 60 years. Among those who reported being sexually active, participants in the raloxifene group experienced significantly greater difficulty with sexual interest (P = .009; mean difference of 0.096 on the scale of 0-3); greater difficulty with sexual arousal...
VASOMOTOR PROBLEMS DIMINISHED WITH TREATMENT

Overall, vasomotor problems diminished with treatment (P<.001). These results were unchanged after controlling for age (data not shown).

**Symptom Severity**

Statistically significant differences were noted between the tamoxifen and raloxifene groups for average severity of symptoms after baseline (Table 2). The raloxifene group experienced significantly greater musculoskeletal problems (P=.002), dyspareunia (P<.001), and weight gain (P<.001). Tamoxifen participants experienced significantly greater vasomotor symptoms (P<.001), bladder problems (P<.001), gynecological problems (P<.001), and leg cramps (P<.001). These treatment differences were unrelated to age for all symptoms except vasomotor symptoms. Overall, vasomotor problems diminished with age and younger (<60 years) raloxifene participants had less severe vasomotor symptoms. However, among those older than 60 years, the treatment difference was muted.

The magnitude of the mean differences in symptom severity between treatment groups was small, typically less than 0.2 on a scale of 0 to 4 (Table 2), with the largest differences seen in vasomotor symptoms and leg cramps (Figure 3). The effect sizes for the significant effects ranged from below 0.1 to 0.3 (Table 2). However, when examined in terms of the percentages of participants at least moderately bothered by their symptoms at 6 months, there was a small difference in vasomotor symptoms among women younger than 60 years: 32% in the tamoxifen group vs 23% in the raloxifene group (Table 3). Leg cramps also showed differences, with 32% at least moderately bothered for participants in the tamoxifen group vs 24% in the raloxifene group. The raloxifene group reported being bothered at least moderately by bladder problems 5% less often than in the tamoxifen group.

The proportion of women who experienced a unit increase in severity (at least 1 point on the scale of 0-4) in vasomotor symptoms was significantly greater among those in the tamoxifen group (P<.001), and the effect of tamoxifen was significantly greater among those younger than 60 years (P=.002 for interaction) and without a hysterectomy (P=.006 for interaction; Table 4). The effect of tamoxifen on leg cramps was slightly stronger among younger women (P=.049), white women (P=.01), and those without a hysterectomy (P=.03). In these analyses, which adjust for baseline severity and participant characteristics, there was no significant treatment effect on bladder problems. A total of 1646 (17.95%) in the tamoxifen group vs 1086 (11.83%) in the raloxifene group experienced a unit increase in bladder problems. For dyspareunia, only treatment (P=.03) and age (P=.004) were significant. A total of 1153 (12.66%) participants in the tamoxifen group vs 1387 (15.20%) in the raloxifene group experienced a unit increase in dyspareunia.

The major findings (for MCS, PCS, CES-D, percentage sexually active, and symptom scales) did not change when the analyses were restricted to assessments before treatment discontinuation (data not shown). When the analyses were further restricted to only those women who discontinued therapy for nonprotocol reasons, the

---

**Table 2. Treatment Differences in Symptom Scales**

<table>
<thead>
<tr>
<th>Symptom Scale</th>
<th>Raw Mean Severity</th>
<th>Treatment Effect</th>
<th>P Value</th>
<th>Effect Size</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>Raloxifene</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forgetfulness</td>
<td>0.99</td>
<td>0.98</td>
<td>NA</td>
<td>.85</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>0.11</td>
<td>0.11</td>
<td>NA</td>
<td>.96</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>1.10</td>
<td>1.15</td>
<td>0.04</td>
<td>.002</td>
</tr>
<tr>
<td>Dyspareunia</td>
<td>0.68</td>
<td>0.78</td>
<td>0.11</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Weight gain</td>
<td>0.76</td>
<td>0.82</td>
<td>0.06</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Vasomotor</td>
<td>0.96</td>
<td>0.85</td>
<td>−0.14</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Bladder</td>
<td>0.88</td>
<td>0.73</td>
<td>−0.16</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Leg cramps</td>
<td>1.10</td>
<td>0.91</td>
<td>−0.2</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Gynecological</td>
<td>0.29</td>
<td>0.19</td>
<td>−0.1</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

*Scores represent symptom severity on a scale of 0 to 4, with higher scores indicating greater severity.†Average severity of assessments after baseline through 60 months.‡Main effect of treatment from regression model. This is an estimate of the increase in average severity with raloxifene relative to tamoxifen, adjusted for baseline severity and, in the case of vasomotor symptoms, also adjusted for age.§A positive treatment effect favors tamoxifen and a negative value favors raloxifene.¶Mean difference/SD.

**Figure 3. Vasomotor Symptom Scale Scores and Leg Cramp Severity Over Time, Averaged by Treatment and Age Group**

Higher scores indicate greater severity. The P value is based on regression of average postbaseline scores.
findings for the MCS, PCS, and CES-D were unchanged, but the treatment differences in rates of sexual activity were larger (odds ratio, 4.67; 95% confidence interval, 1.27-17.08; \(P = .002\)). For symptom scales in this subset, the \(P\) values and most of the effect sizes were unchanged, except that the benefit for raloxifene was increased for gynecological symptoms (effect size, 0.4) and leg cramps (effect size, 0.3).

**COMMENT**

There were no significant differences between tamoxifen and raloxifene in patient-reported outcomes for physical and mental health or depressive symptoms, and scores on all of these measures were well within the normal ranges for healthy women of this age. The significant differences in the role physical and social function scales were small relative to established standards for minimal clinically important differences in these scales.31

There were, however, significant differences in sexual function in favor of tamoxifen. A greater percentage of the tamoxifen group was sexually active at nearly every assessment time point. That effect was quite large when comparing participants who had discontinued therapy early. There were also significant but small differences (in favor of tamoxifen) among those who were sexually active in terms of sexual interest, arousal, and ability to enjoy sex. These differences are likely related to the associated reports of increased vaginal discharge and decreased vaginal dryness among women treated with tamoxifen in this trial. Women in both groups of the trial were provided with the opportunity to use vaginal lubricants and low-dose vaginal estrogen preparations. Future evaluation of these differences in sexual functioning will explore whether women assigned to raloxifene used these preparations at a different frequency.

Although symptom severity was generally low in this postmenopausal sample, we demonstrated significantly less severe gynecological prob-

### Table 3. Distribution of Symptom Severity by Treatment Group

<table>
<thead>
<tr>
<th>Symptom and Score Distribution*</th>
<th>Baseline, No. (%)</th>
<th>6 Months, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>Raloxifene</td>
</tr>
<tr>
<td>Forgetfulness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9727</td>
</tr>
<tr>
<td>1-4 5576 (57)</td>
<td>5579 (57)</td>
<td>5110 (55)</td>
</tr>
<tr>
<td>2-4 1983 (20)</td>
<td>1978 (20)</td>
<td>2266 (24)</td>
</tr>
<tr>
<td>3-4 630 (6)</td>
<td>599 (6)</td>
<td>814 (9)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 366 (4)</td>
<td>376 (4)</td>
<td>466 (5)</td>
</tr>
<tr>
<td>2-4 71 (1)</td>
<td>77 (1)</td>
<td>110 (1)</td>
</tr>
<tr>
<td>3-4 18 (&lt;1)</td>
<td>32 (&lt;1)</td>
<td>28 (&lt;1)</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 4958 (51)</td>
<td>4956 (51)</td>
<td>4412 (48)</td>
</tr>
<tr>
<td>2-4 1970 (20)</td>
<td>1967 (20)</td>
<td>1944 (21)</td>
</tr>
<tr>
<td>3-4 611 (6)</td>
<td>570 (6)</td>
<td>629 (7)</td>
</tr>
<tr>
<td>Dyspareunia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 3078 (32)</td>
<td>3121 (32)</td>
<td>2945 (32)</td>
</tr>
<tr>
<td>2-4 1363 (14)</td>
<td>1388 (14)</td>
<td>1340 (14)</td>
</tr>
<tr>
<td>3-4 556 (6)</td>
<td>589 (6)</td>
<td>600 (6)</td>
</tr>
<tr>
<td>Weight gain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 3417 (35)</td>
<td>3396 (35)</td>
<td>3871 (42)</td>
</tr>
<tr>
<td>2-4 1583 (16)</td>
<td>1592 (16)</td>
<td>1718 (23)</td>
</tr>
<tr>
<td>3-4 698 (7)</td>
<td>693 (7)</td>
<td>1184 (13)</td>
</tr>
<tr>
<td>Vasomotor symptoms (age &lt;60 y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 5742</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 2851 (50)</td>
<td>2855 (50)</td>
<td>3620 (66)</td>
</tr>
<tr>
<td>2-4 1131 (20)</td>
<td>1174 (20)</td>
<td>1767 (32)</td>
</tr>
<tr>
<td>3-4 236 (4)</td>
<td>261 (5)</td>
<td>496 (9)</td>
</tr>
<tr>
<td>Vasomotor symptoms (age ≥60 y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 4001</td>
<td>4023</td>
<td>3816</td>
</tr>
<tr>
<td>1-4 1190 (30)</td>
<td>1155 (29)</td>
<td>1668 (44)</td>
</tr>
<tr>
<td>2-4 431 (11)</td>
<td>389 (10)</td>
<td>761 (20)</td>
</tr>
<tr>
<td>3-4 81 (2)</td>
<td>75 (2)</td>
<td>185 (5)</td>
</tr>
<tr>
<td>Bladder problems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 3208 (33)</td>
<td>3232 (34)</td>
<td>3728 (40)</td>
</tr>
<tr>
<td>2-4 1246 (13)</td>
<td>1305 (13)</td>
<td>1730 (19)</td>
</tr>
<tr>
<td>3-4 447 (5)</td>
<td>516 (5)</td>
<td>770 (8)</td>
</tr>
<tr>
<td>Leg cramps</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 3371 (35)</td>
<td>3432 (35)</td>
<td>5140 (55)</td>
</tr>
<tr>
<td>2-4 1318 (14)</td>
<td>1336 (14)</td>
<td>2922 (32)</td>
</tr>
<tr>
<td>3-4 422 (4)</td>
<td>460 (5)</td>
<td>1415 (15)</td>
</tr>
<tr>
<td>Gynecological problems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. 9743</td>
<td>9769</td>
<td>9273</td>
</tr>
<tr>
<td>1-4 420 (4)</td>
<td>389 (4)</td>
<td>1070 (12)</td>
</tr>
<tr>
<td>2-4 37 (&lt;1)</td>
<td>34 (&lt;1)</td>
<td>149 (2)</td>
</tr>
<tr>
<td>3-4 2 (&lt;1)</td>
<td>2 (&lt;1)</td>
<td>17 (&lt;1)</td>
</tr>
</tbody>
</table>

*Scores are defined as 1-4 = at least slightly bothersome; 2-4 = at least moderately bothersome; 3-4 = at least quite a bit bothersome. Categories are grouped to help patients see how many individuals experienced adverse effects at or above the various levels of severity.
lems, vasomotor symptoms, bladder control problems, and leg cramps among raloxifene-treated women. However, the effect sizes for the differences in mean severity ranged from 0.2 to 0.3. Effect sizes were as large as 0.4 when comparing only the subset of participants who discontinued therapy early. A systematic literature review covering a variety of patient-reported outcomes demonstrated that the minimal treatment difference that is clinically significant is typically found to be an effect size of 0.5, although this ranged as low as 0.2. That is consistent with conventional standards, in which 0.5 is a moderate effect size and 0.2 is a small one. Therefore, the mean symptom differences found in this study in favor of raloxifene can be considered at or just below minimal clinical significance. Nevertheless, the differences in the percentages of women who were bothered by these 4 symptoms demonstrated that the treatment difference was clinically apparent for a nonnegligible proportion of the participants. In addition, the proportions experiencing at least a 1-unit increase in severity were substantial. There were also significant differences in favor of tamoxifen in the average severity of musculoskeletal symptoms, dyspareunia, and weight gain, but the effect sizes did not exceed 0.1, and therefore are not likely to be clinically significant. The treatment differences in the percentages of women who were bothered by these 3 symptoms were small. The slight benefit of raloxifene in terms of symptoms is consistent with the increased treatment adherence that was observed in that group.

There was no subgroup of patients based on age, race, or hysterectomy status for whom the treatment difference in vasomotor symptoms and leg cramps was not substantial. Treatment effects were found to be greatest among the youngest participants without a hysterectomy. The reason for this finding is uncertain, although it is possible that women without a hysterectomy (and intact ovaries) would have more residual hormonal secretion of androgens and estrogens, and thus be more susceptible to the antiestrogen effects of tamoxifen. In contrast, those women with a prior hysterectomy may have already experienced diminished ovarian androgen and estrogen secretion for some time. For leg cramps, the effect of tamoxifen was strongest among white women.

The observation in STAR that vasomotor symptoms increased initially across age groups in each treatment group is largely consistent with results from other trials. The association between vasomotor symptoms and tamoxifen has been well-established and even stronger in the BCPT due to the younger age of participants. Vasomotor symptoms were also associated with raloxifene in the MORE study. In addition, a pooled analysis of 8 randomized trials performed by Eli Lilly and Co. found a consistent increase in hot flashes with raloxifene relative to placebo, hormone replacement, or unopposed estrogen. In contrast, however, a recent study found no increase in hot flashes with 12 weeks of raloxifene vs placebo after discontinuation of combined estrogen-progestin therapy. Another study compared hot flashes between raloxifene and placebo within early (<6 years) and later postmenopausal groups separately, with evaluations at 2 and 8 months of treatment, and found that raloxifene did increase hot flashes in the early postmenopausal group but not in the later postmenopausal group. Vasomotor symptoms in STAR diminished during the course of treatment in all age and treatment groups. This could be partially explained by aging. It is probably not related to discontinuation of therapy in those participants experiencing the most severe symptoms because the same trends were seen in the during-treatment assessments of participants who discontinued therapy early. Future analyses will examine the changes in symptoms after treatment discontinuation.

The present evidence regarding bladder control together with evidence from the MORE and BCPT indicates that raloxifene has no effect on urinary incontinence while tamoxifen increases urinary incontinence. In the QOL substudy of the Royal Marsden Hospital Tamoxifen Chemo-prevention Trial and the International Breast Cancer In-

### Table 4. Percentage of Women With Symptom Severity Increase of ≥1 from Baseline to 6 Months

<table>
<thead>
<tr>
<th></th>
<th>Tamoxifen, No./Total (%)</th>
<th>Raloxifene, No./Total (%)</th>
<th>Difference, %</th>
<th>P Value*</th>
<th>Tamoxifen, No. (%)</th>
<th>Raloxifene, No. (%)</th>
<th>Difference, %</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vasomotor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>1433/5384 (27)</td>
<td>832/5378 (15)</td>
<td>12</td>
<td>&lt;.001</td>
<td>2245/5399 (42)</td>
<td>1688/5354 (32)</td>
<td>10</td>
<td>.23</td>
</tr>
<tr>
<td>≥60</td>
<td>770/3780 (20)</td>
<td>541/3803 (14)</td>
<td>6</td>
<td>.002</td>
<td>1553/3762 (41)</td>
<td>1274/3786 (34)</td>
<td>7</td>
<td>.09</td>
</tr>
<tr>
<td><strong>Race†</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>2065/8595 (24)</td>
<td>1272/8606 (15)</td>
<td>9</td>
<td>.36</td>
<td>3592/8567 (42)</td>
<td>2767/8569 (32)</td>
<td>10</td>
<td>.01</td>
</tr>
<tr>
<td>Nonwhite</td>
<td>138/569 (24)</td>
<td>101/575 (18)</td>
<td>6</td>
<td>.20</td>
<td>206/564 (37)</td>
<td>195/571 (34)</td>
<td>3</td>
<td>.01</td>
</tr>
<tr>
<td><strong>Hysterectomy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1118/4651 (24)</td>
<td>764/4676 (16)</td>
<td>8</td>
<td>.31</td>
<td>1918/4646 (41)</td>
<td>1568/4654 (34)</td>
<td>7</td>
<td>.15</td>
</tr>
<tr>
<td>No</td>
<td>1085/4513 (24)</td>
<td>609/4505 (14)</td>
<td>10</td>
<td>.006</td>
<td>1880/4485 (42)</td>
<td>1394/4486 (31)</td>
<td>11</td>
<td>.03</td>
</tr>
<tr>
<td><strong>All</strong></td>
<td>2203/9164 (24)</td>
<td>1373/9181 (15)</td>
<td>9</td>
<td>&lt;.001</td>
<td>3798/9131 (42)</td>
<td>2962/9140 (32)</td>
<td>10</td>
<td>.14</td>
</tr>
</tbody>
</table>

*P values are shown for the main effect of the characteristic and the interaction of the characteristic with treatment assignment.
†The nonwhite category includes black, Hispanic, and other.
irritability. It is noteworthy that lon-
difference in favor of tamoxifen in de-
QOL substudy revealed a numerical
scores. The 48-month symptom check-
and nonsignificance for the anxiety
marginal significance for the GHQ-30
anxiety Inventory) slightly favored
tamoxifen over placebo, with only
change in leg cramps among
participants treated with tamoxifen vs
those treated with raloxifene was an
unexpected finding. Leg cramps were
associated with raloxifene in the MORE
study and in the Lilly pooled analy-
However, we found no prior re-
ports linking leg cramps with tamoxi-
fen. For example, the 1995 Physician’s
Desk Reference (PDR) did not list leg
cramps as an anticipated adverse effect
tamoxifen. The BCPT symptom
checklist did not include leg cramps, al-
though the consent for that protocol did
anticipate leg cramps as a rare adverse
effect.

Together with the BCPT, Royal
Marsden, and IBIS-I trials, STAR con-
firmed that tamoxifen does not impair
mental health. In the Royal Marsden
and IBIS-I QOL substudy, longitudi-
nal measures of psychological morbid-
ity (General Health Questionnaire
(GHQ-30)) and anxiety (State-Trait
Anxiety Inventory) slightly favored
tamoxifen over placebo, with only
marginal significance for the GHQ-30
and nonsignificance for the anxiety
scores. The 48-month symptom check-
list in the Royal Marsden and IBIS-I QOL
substudy revealed a numerical
difference in favor of tamoxifen in de-
pression, mood swings, anxiety, and
irritability. It is noteworthy that lon-
gitudinal data for several mental
health–related measures in all treat-
ment groups in the BCPT, Royal
Marsden–IBIS-I, and STAR studies
showed a decline initially after the start
of therapy, followed by a partial re-
turn to baseline levels. The change was
small (eg, about 1.5 points in the CES-D
scores in both treatment groups in both
the BCPT and STAR). Possible rea-
sons for this phenomenon, including
the effects of enrollment screening or
the impact of participating in a preven-
tion trial, have been explored else-
where.

Cognitive change in STAR will be
evaluated in much greater detail in
NSABP protocol Co-STAR. This ancil-
lar study recruited 1510 women to un-
dergo annual neuropsychological bat-
teries focusing on verbal and nonverbal
memory, other cognitive abilities, and
mood. The primary hypotheses are that
the cognitive changes with age will not be
different between tamoxifen and ra-
loxifene and that the changes with
tamoxifen will be similar to that seen for
placebo in the Women’s Health Initia-
tive Study of Cognitive Aging. The pre-
sent analysis of the symptom check-
list is consistent with these hypotheses:
we found that self-reported forgetful-
ness did not change significantly over
time, nor did it differ by treatment (data
not shown). This observation is also
consistent with past data. Two double-
blind randomized trials demonstrated
a protective effect of raloxifene against
cognitive decline but only for raloxi-
fenegivenat120mg/dandnotat
60mg/d used in STAR.

The BCPT symptom checklist included 3
cognitive items, forgetfulness, difficulty
centricating, and easily distracted. No

treatment differences were reported for
these items in the BCPT.

Patient-reported outcomes are particu-
larly useful in the setting of pre-
vention, where individuals must make a
choice between an agent with pos-
sible adverse effects and an abstract risk
of cancer. A woman’s physician can help
guide her based on anecdotal evi-
dence from the physician’s own clin-
ical practice. However, anecdotal evi-
dence has at times been misleading.

Since the 1970s, anecdotal evidence re-
garding clinical outcomes has been re-
placed with rigorously standardized
clinical trials. Symptom and QOL evi-
dence must also be rigorously evalu-
ated. The NSABP’s STAR trial, with its
large-scale symptom evaluation and
well-powered QOL substudy, pro-
vides a comprehensive, detailed view
of the patient experience using raloxi-
fene and tamoxifen. Both of these
agents are indicated for prevention in
large populations, so these results can
be widely used as tools in decision mak-
ing or in helping a woman anticipate
and cope with the sequelae of her chos-
en agent.

Published Online: June 5, 2006 (doi:10.1001/jama.295.23.joc00075).

Author Affiliations: National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatis-
tical Centers (Drs Land, Wickerham, Ritter, and Cos-
tantino and Mr Lee), Department of Biostatistics, Graduate School of Public Health, University of Pitts-
burgh (Drs Land, Ritter, and Costantino and Mr Lee), Allegheny General Hospital (Drs Wickerham and
Wolmark), the University of Pittsburgh Cancer Insti-
tute (Drs Vogel and Land), and Magee Women’s Hospital (Dr Vogel), Pittsburgh, Pa; Colorado Cancer
Research Program, Denver (Dr Pajon); Community Clinical Oncology Program Central Illinois, Decatur
Memorial Hospital, Decatur (Dr Wade); Community Clinical Oncology Program Wichita, Wichita, Kan
(Dr Dakhil); Oklahoma Community Clinical Oncology Program, Warren Cancer Research Foundation,
Tulsa (Dr Lockhart); University of California Los Angeles Schools of Public Health and Medicine, Jonson
Comprehensive Cancer Center (Dr Ganz).

Author Contributions: Dr Land had full access to all of
the data in the study and takes responsibility for the integ-

d continuity of the data and the accuracy of the data analysis.

Study concept and design: Wickerham, Costantino,
Wolmark.

Acquisition of data: Land, Costantino, Ritter, Vogel,
Pajon, Wade, Dakhil, Lockhart.

Analysis and interpretation of data: Land, Vogel, Lee,
Wolmark.

Drafting of the manuscript: Land, Costantino, Vogel,
Lee, Wade, Ganz.

Critical revision of the manuscript for important in-
tellectual content: Wickerham, Ritter, Vogel, Pajon,
Dakhil, Lockhart, Wolmark.

Statistical analysis: Land, Lee.

Obtained funding: Costantino.

Administrative, technical, or material support: Land,
Wickerham, Costantino, Ritter, Vogel, Pajon, Wade,
Lockhart, Wolmark.

Study supervision: Costantino, Vogel, Pajon, Wol-
mark, Ganz.

Financial Disclosures: Dr Wickerham has reported serv-
ing as a consultant for and on the speaker’s bureau of
AstraZeneca Pharmaceuticals; Dr Vogel has re-
ported serving on the speaker’s bureau of AstraZen-
ecaPharmaceuticalsandElilillyandCompany.

Role of the Sponsor: The study sponsors had no role
in any aspect of study design, data collection, anal-
ysis and interpretation of data, or in the development
of the manuscript. Per contractual arrangement, the
manuscript was submitted to AstraZeneca and Eli Lily
before submission.

Acknowledgment: We thank Barbara C. Good, PhD,
Director of Scientific Publications for the National Sur-
gical Adjuvant Breast and Bowel Project, and Wendy
Rea, BA, for editorial assistance. Dr Good and Ms Rea
are employees of the NSABP. They were not com-
pensated beyond their normal salaries for this work.
We also thank the courageous participants without
whom this trial could not have been accomplished.

©2006 American Medical Association. All rights reserved.
REFERENCES
16. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
ent effects at the cellular level. L-NAME is relatively nNOS and eNOS selective. However, it is not clear that L-NAME is more potent in vivo, especially since it is believed that iNOS is the important target in patients with cardiogenic shock. Refractory shock is characterized by lower-than-expected systemic vascular resistance and hypotension, both potential effects of excess NO. Effects of NOS inhibition in patients with cardiogenic shock should differ from normal volunteers. Importantly, the initial positive single-center experience with NOS inhibition in patients with cardiogenic shock used L-NMMA. We believe our conclusion is valid: L-NMMA, at the dose and duration studied in TRIUMPH, had no effect on mortality. It is possible that other dosing strategies, perhaps taking into consideration baseline renal function, or other NOS inhibitors might have a different effect. Determining this would require another large randomized clinical trial with mortality outcomes.

Robert A. Harrington, MD
John H. Alexander, MD
Duke University
Durham, North Carolina
Judith S. Hochman, MD
New York University
New York, New York
Vladimir Dzavik, MD
University of Toronto
Toronto, Ontario, Canada
Frans J. Van de Werf, MD
University Hospital of Gasthuisberg
Leuven, Belgium

Financial Disclosures: All members of the writing committee (Drs Alexander, Reynolds, Dzavik, Harrington, Van de Werf, and Hochman) reported receiving institutional research support from ArgiNOx Pharmaceuticals for their work on TRIUMPH. Dr Hochman reported receiving honoraria from ArgiNOx and Procter and Gamble and performed consulting for Datascope. Dr Dzavik reported receiving honoraria from Datascope.


CORRECTIONS

In the Original Contribution entitled “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial” published in the June 21, 2006, issue of JAMA (2006;295(23):2727-2741), incorrect data were reported. In Table 2 on page 2731, the risk ratio (RR) for estrogen receptor–positive patients should have been reported as 0.94. In the “Invasive Breast Cancer” panel of Figure 2 on page 2732, the number at risk in the raloxifene group at 36 months should have been reported as 6702. In the “invasive” cancer row of Table 3 on page 2732, the rate per 1000 for tamoxifen should have been reported as 1.99, the difference in rate per 1000 as 0.74, and the RR as 0.63. Also in Table 3, in the “hysterectomy during follow-up” row, the number of events for tamoxifen should have been reported as 221 and for raloxifene as 87, the rate per 1000 for tamoxifen as 12.24 and for raloxifene as 4.72, the difference per 1000 as 7.52, and the RR (95% confidence interval [CI]) as 0.39 (0.30-0.50). On page 2733, top of column 1, the annual incidence rate for tamoxifen should have been reported as 1.99, the RR for raloxifene as 0.63, and the cumulative incidence rate through 7 years for tamoxifen as 14.6. Also on page 2733, end of first paragraph in column 2, the number of hysterectomies performed in those assigned to tamoxifen should have been reported as 221 and in those assigned to raloxifene as 87, and the RR (95% CI) as 0.39 (0.30-0.50). In the “Invasive Uterine Cancer” panel of Figure 3 on page 2733, numbers at risk in the raloxifene group at 18, 36, 54, and 72 months should have been reported as 4311, 3233, 2103, and 409, respectively; in the tamoxifen group, the numbers at risk at these same points should have been reported as 4301, 3120, 1984, and 371, respectively. In Table 5 on page 2735, the rate per 1000 for ischemic heart disease in the tamoxifen group should have been reported as 2.99 and the difference per 1000 as –0.30. In the first paragraph of the Comment section on page 2736, the terms “raloxifene” and “tamoxifen” were reversed in the second sentence; the sentence should have read “The cumulative incidence rates were 25.1 per 1000 women (tamoxifen) vs 24.8 per 1000 (raloxifene) (P = .83).” Also, a trial site and its personnel were inadvertently omitted: in the list of active NSABP STAR P-2 clinical centers appearing on page 2739, “Boston Medical Center, Boston, Mass: Marianne N. Prout (PI), Liz Pottier (PC),” should have appeared between the entries for Boca Raton Community Hospital and CAIC Health Education and Research Center.

In the Original Contribution entitled “Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study” published in the April 11, 2007, issue of JAMA (2007;297[14]:1551-1561), incorrect data were reported in 3 tables. In Table 1, the number of events for tamoxifen who withdrew consent at some point during follow-up should have been reported as 221 and for raloxifene as 87, the rate per 1000 for tamoxifen as 12.24 and for raloxifene as 4.72, the difference per 1000 as 7.52, and the RR (95% confidence interval [CI]) as 0.39 (0.30-0.50). In the “Invasive Uterine Cancer” panel of Figure 3 on page 2733, numbers at risk in the raloxifene group at 18, 36, 54, and 72 months should have been reported as 4311, 3233, 2103, and 409, respectively; in the tamoxifen group, the numbers at risk at these same points should have been reported as 4301, 3120, 1984, and 371, respectively. In Table 5 on page 2735, the rate per 1000 for ischemic heart disease in the tamoxifen group should have been reported as 2.99 and the difference per 1000 as –0.30. In the first paragraph of the Comment section on page 2736, the terms “raloxifene” and “tamoxifen” were reversed in the second sentence; the sentence should have read “The cumulative incidence rates were 25.1 per 1000 women (tamoxifen) vs 24.8 per 1000 (raloxifene) (P = .83).” Also, a trial site and its personnel were inadvertently omitted: in the list of active NSABP STAR P-2 clinical centers appearing on page 2739, “Boston Medical Center, Boston, Mass: Marianne N. Prout (PI), Liz Pottier (PC),” should have appeared between the entries for Boca Raton Community Hospital and CAIC Health Education and Research Center.

In the Original Contribution entitled “Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial” published in the June 21, 2006, issue of JAMA (2006;295[23]:2742-2751) reported incorrect data and included incorrect wording. On page 2745, in Figure 1, the P value for the SF-36 Mental Component Summary should have been .14 and for the SF-36 Physical Component Summary, the P value should have been .23. On the same page the P values should have been reported similarly in text: “(P = .14, MCS and P = .23, PCS).” Also, on the same page, the text that reads “Forms were not expected after death or consent withdrawal, which occurred at some point during follow-up for 197 women (1.0%) in the tamoxifen and 1352 (6.8%) in the raloxifene groups” should have read “Forms were not expected from the 207 women (1.0%) who died or from the 1352 women (6.8%) who withdrew consent at some point during follow-up.”

In the Original Contribution entitled “Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study” published in the April 11, 2007, issue of JAMA (2007;297[14]:1551-1561), incorrect data were reported in 3 tables. In Tables 1 and 2, the gene symbol LPA should have been identified as LPL and in Table 3, the mean age for men with acute coronary syndrome (ACS) should be 60.7 years and for the controls, 60.0 years.